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Interventional Radiology (IR) is occupying an increasingly prominent role in the care of patients with cancer, with involvement
frominitialdiagnosis,rightthroughtominimallyinvasivetreatmentofthemalignancyanditscomplications.Adequatediagnostic
samples can be obtained under image guidance by percutaneous biopsy and needle aspiration in an accurate and minimally
invasive manner. IR techniques may be used to place central venous access devices with well-established safety and eﬃcacy.
Therapeutic applications of IR in the oncology patient include local tumour treatments such as transarterial chemo-embolisation
and radiofrequency ablation, as well as management of complications of malignancy such as pain, organ obstruction, and venous
thrombosis.
1.Introduction
Management of malignancy is now in the domain of the
multi-disciplinary team and Interventional Radiology (IR)
is occupying a prominent role in this environment [1, 2].
IR input begins with establishing the initial diagnosis of
cancer, and involvement now extends to minimally invasive
treatment of malignancy, often in combination with other
modalities. IR has also assumed an important place in the
management of the complications of malignancy, which may
result from malignancy itself or secondary to treatment. This
paper provides an updated overview of the role of IR in the
management of the oncology patient.
2. InterventionalRadiology inthe
DiagnosisofCancer
Appropriate treatment of malignancy is dependent on a
timely deﬁnitive diagnosis and on accurate staging of dis-
ease. While non-invasive imaging techniques have improved
assessment and staging for cancer, histologic conﬁrmation
remains the gold standard for deﬁnitive diagnosis of many
tumours. Biopsies to establish histological diagnosis are
increasingly performed using minimally invasive techniques
by interventional radiologists [3]. The direct visualisation
enabled by image guidance during biopsy permits safe
passage of a needle into an organ or mass, improving
eﬃcacy and minimising trauma to surrounding structures
(Figure 1). These minimally invasive techniques are applica-
bletoawiderangeofbiopsysitesand,inmostorgansystems,
have been demonstrated to be highly accurate with a low
complication rate [3]. In biopsy planning, modern cross-
sectional imaging techniques help deﬁne lesion location,
accessibility, and suitability for biopsy and aid in ensuring
the correct lesion is sampled in the context of multiple
lesions. In selected cases where lesions are present in more
than one organ, percutaneous biopsy may be used to
concurrently conﬁrm histological diagnosis and establish
oncological staging by sampling the lesion suspicious for
metastasis [4]( Figure 2). With improving histological and
cytologicaltechniques,particularlyinimmunohistochemical
analysis, histological and possibly molecular examination
may determine with more certainty the probable under-
lying primary tumour site and can predict sensitivity to
chemotheraputic drugs in some cases [5]. In cases where
surgical biopsy remains the preferred diagnostic approach,
pre-operative tumour localisation can be performed with
image guidance in many situations; an example of this is
wire-localisation prior to excisional breast biopsy [6]a n d
in the chest to guide video-assisted thorascopic surgery2 Radiology Research and Practice
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Figure 1: 64-year-old man with lung lesion: (a) CT scan of chest in supine position shows left-sided lung lesion. (b) A 19-gauge needle has
been positioned within the lesion under CT guidance and core biopsy is then performed using coaxial technique.
(VATS) for removal of lung nodules that would otherwise
require open thoracotomy [7]. Increasingly, percutaneous
biopsy is utilised for microbiological diagnosis of lesions
suspicious for opportunistic infections (particularly fungal)
in oncology patients with febrile neutropenia [8]. Choice
of image guidance modality is multifactorial and there are
many available options. Ultrasound oﬀers the beneﬁt of real-
time imaging allowing accurate monitoring of the needle
trajectory through tissues en route to the target lesion, with
the dual advantage of avoiding patient and staﬀ exposure
to ionising radiation during the biopsy [9]. When lesions
are visible by ultrasound, with suitable equipment and
appropriate operator experience, this modality can provide
equivalent or superior guidance to CT at time of biopsy
[9]. CT guidance oﬀers enhanced anatomical detailing and
delineation with more precise needle localisation when
compared to ultrasound [9]. Complications, if any, are easily
recognised on CT scan. It ﬁnds particular utility in thoracic,
pelvic, and retroperitoneal biopsies which are frequently
diﬃcult to perform under ultrasound guidance [8]. The
main disadvantage is exposure to ionising radiation; both
patient and, to a lesser extent, staﬀ are exposed to this at
time of biopsy, and the extent of such radiation exposure
is related to the total scan time, scan parameters such
as peak tube kilovoltage (kVp) and milliamperage (mA),
the body part imaged, and the size of the patient. CT
ﬂuoroscopy is an additional tool which allows near real-
time imaging of needle trajectory, which when appropriately
used will shorten procedure duration [10]. Fluoroscopic
images are acquired at a lower milliamperage (mA) than
standard CT guidance permitting lower radiation dose to the
patient, though the radiation dose to physician and assisting
staﬀ is increased [11]. Use of recently available modality
fusion image guidance systems during ultrasound-guided
procedures, where there is real-time projection of a needle
or probe onto a pre-existing CT or MRI image, improves
accuracy of needle placement while reducing radiation
exposure to patient, physician, and staﬀ [12].
3. InterventionalRadiology inthe
Treatment of Cancer
3.1. Central Venous Access. An integral part of care of the
cancer patient is intermediate and longer-term vascular
accessasameansofmedication,chemotherapy,orparenteral
nutrition administration, as well as allowing repeated blood
samplingwithoutneedforvenepuncture.Onanannualbasis
in the UK, over 200,000 central access devices are inserted,
many in oncology patients and while previously inserted
by anaesthetists and surgeons, IR techniques are now
commonlyemployedtositethesedevices[13].Image-guided
percutaneous central venous access involves placement of a
catheter with its tip at the cavoatrial region or right atrium
with assistance of real-time imaging, usually ﬂuoroscopy
or ultrasonography [14]. Intraprocedural complications of
centralaccesscatheterinsertion are typically related toinjury
to surrounding structures or catheter malposition, and thus
occur less frequently when performed under image guidance
thanwithblindtechniqueguidedbyexternallandmarks[14–
16]. The right internal jugular vein is the most commonly
used central access route, but image guidance is particularly
useful to map alternative access routes in diﬃcult cases
[17]. The longer-term complications of central access devices
include thrombosis and infection and rates of these are
unaﬀected by insertion technique. Patients with cancer have
a 4- to 6- fold increased risk of thrombosis compared with
the general population, a risk which is further increasedRadiology Research and Practice 3
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Figure 2: 72-year-old-man with right lung mass and adrenal mass: biopsy of adrenal mass facilitates histological diagnosis and deﬁnitive
staginginoneprocedure.(a)CTscanshowsrightupperlobespiculatednodule.Thereisseverebackgroundemphysema,whichincreasesthe
riskassociatedwithpercutaneouslungbiopsy.(b)CTscanoftheupperabdomenshowsaleftadrenalmass(arrow),suspiciousformetastatic
disease. (c) Percutaneous biopsy of left adrenal gland in left lateral decubitus position achieves histological diagnosis and conﬁrms advanced
staging. The risk of pneumothorax is avoided.
by placement of a CVC [18, 19]. Clinically overt CVC-
related deep venous thrombosis (DVT) in cancer patients
can have an incidence as high as 28% [20, 21]. In cancer
patients with CVC-related DVT, the incidence of clinically
overt pulmonary embolism (PE) varies between 15% and
25% [20, 21]. The incidence of thromboembolism has
been reported to increase with large multilumen catheters,
those in left sided veins, and those inserted into patients
with inherited and acquired prothrombotic tendencies [22].
Thrombotic prophylaxis with low dose warfarin and heparin
has not been shown to reduce the incidence of thrombosis
in patients with central access catheters, so anticoagulation
prophylaxis is not currently recommended [23, 24]. No
uniformly accepted method of therapeutic anti-coagulation
or duration of treatment exists, with most patients treated
withanticoagulationtherapyfor6weekstoayear,dependent
on the extent of the thrombus, response to initial therapy,
and whether thrombophilic factors persist [23].
3.2. Arterial Embolisation Techniques. Minimally invasive
image-guided cancer treatments as an adjunct or alternative
to surgery are increasingly being used in the manage-
ment of malignancy [25, 26]. Delineation of the arterial
supply of a solid tumour by contrast enhanced CT or
MRI facilitates devascularisation of neoplastic tissue by
transcatheter embolisation [27]. Bland mechanical occlusion
can be achieved by Gelfoam (Upjohn, Kalamazoo, MI),
polyvinyl alcohol, blood clots, Amplatzer occlusion devices,
coils and embospheres (Biosphere medical, Rockland, MA)
introduced into the tumour bed and lodged in the feed-
ing vessel following ﬂuoroscopic guided selective arterial
catheterisation by IR [28–30]. This technique can be used4 Radiology Research and Practice
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Figure 3: 68-year-old man with hepatocellular carcinoma in segment VI of liver: (a) selective cannulation of right hepatic artery performed
demonstrating tumour blush pre-embolisation with (b) absence of this tumour blush post infusion of 40mg of doxorubicin on 300–500µm
beads into this branch.
alone as the primary modality of treatment, where inter-
ruption of the aﬀerent blood supply to the tumour induces
hypoxia and inhibits tumour growth, or in conjunction with
ablative treatments or conventional surgery [28]. In the case
of hepatic neoplasms, absence of arterial phase enhancement
of a previously hypervascular lesion when reimaged 4 to 6
weeks following treatment suggests success [25, 31]. Arterial
embolisation also has a role prior to surgical resection of
hypervasculartumoursinaneﬀorttoreduceoperativeblood
losses. In a palliative setting, embolisation may be used to
reduce tumour burden and aid symptomatic relief [32]. In
acute haemorrhagic complications of malignancy, such as
massive haemoptysis, haematemesis or pleural or peritoneal
haemorrhage, IR embolisation of the bleeding vessel has
therapeutic applications also [32].
Transarterial chemoembolisation (TACE) is a modiﬁ-
cation of the above technique which is usually applied
to hepatic tumours. Following selective hepatic artery
catheterisation, a single or combination chemotherapy agent
combined with a delivery agent, usually ethiodized oil
(Ethiodol, Savage, Melville, NY), is directly infused along
with an embolic agent that occludes the ﬂow through the
catheterised artery [28]( Figure 3). Hepatic tumours rely on
the hepatic artery for the majority of their blood supply, as
demonstrated by a tenfold greater uptake of radioisotope,
in the form of radio-labelled albumen, following hepatic
artery infusion when compared to portal vein infusion
[33]. The advantage of TACE over systemic chemotherapy
is that delivery of the chemotherapeutic agent is targeted
at the lesion allowing a higher local concentration of the
agent and lower systemic doses. Embolisation of the artery
increases the dwell time of the chemotherapeutic agent.
Chemoembolisation has the advantage of being repeatable
and treatment may involve a number of sessions until the
entire tumour bed is devascularised [8]. The liver tolerates
this procedure because of its dual blood supply and, to avoid
hepatic necrosis, chemoembolisation should be performed
with caution in the absence of portal vein patency or a
suﬃcient alternative blood supply to the liver [34]. Drug-
elutingbeads(DEB)compriseparticlesofvariablesizewhich
bind and elute doxorubicin in a predictable manner. They
may be used in the place of standard chemotherapeutic
agent infusion during the TACE procedure in patients with
hepatocellular carcinoma and have shown promising results
to date, making them likely to be of therapeutic beneﬁt in the
future [35].
Radioembolisation, a novel form of liver-directed
brachytherapy, is another modality with potential for
focussed treatment of hepatic malignant lesions [36, 37].
Selective catheter placement allows introduction of beta-
radiation emitting radioisotopes directly into the tumour
mass by means of microspheres (glass, albumen, or resin)
[38]. Depending on the nature of the tumour, various
radionuclides are used, including Yttrium 90, rhenium, and
holmium [36, 39]. Beta radiation has a very low penetration
(approximately 2.5mm in human tissues), thus its necrosing
eﬀects are localised [40]. The concurrent emission of a small
amount of gamma radiation, which is capable of penetrating
the body tissues, allows detection of the radiolabelled
particles by a gamma camera and appropriate localisation of
isotope can be conﬁrmed. Accurate transcatheter delivery of
radioisotopes has been shown to be safe, with eﬃcacy con-
ﬁrmed on preliminary results [41, 42]. Radioembolisation
has been reported to produce a meaningful response and
disease stabilisation in patients with advanced unresectable
liver metastases, and may be potentially very useful in
patients with chemorefractory metastatic colorectal cancer
[43]. Technically radioembolisation is more diﬃcult than
chemoembolisation,withpotentialforinadvertentnontarget
embolisationofotherorgans,particularlythestomach,small
bowel, and gall-bladder, causing slow-healing gastrointesti-
nal ulcers or cholecystitis respectively [40]. Other potential
adverse eﬀects include pneumonitis and radioembolisation-
induced liver disease, therefore use should be restricted to
patients with a serum bilirubin of less than 2mg/dL and to
patientswithoutsigniﬁcanthepatopulmonaryshunting[35].
3.3. Gene Therapy. Advances in molecular oncology and
tumour immunology have facilitated the development of
gene therapy in the treatment of malignancy [44]. StrategiesRadiology Research and Practice 5
employedincludestimulationoftheimmuneresponsetothe
tumour, reduction of oncogenic expression, restoration of
tumour suppressor gene function, alteration of susceptibility
of proliferating tumour cells to chemotherapeutics, and
modulation of angiogenesis [44, 45]. In an IR technique
similar to that used in chemoembolisation, genetic agents
may be administered directly into the tumour mass by
selective arterial injection, after which the vessel is embolised
thus limiting adverse eﬀects and prolonging agent dwell time
which is believed to improve genetic transfer rate [46]. As
DNA has a limited ability to cross cell membranes, vector
agents are used to optimise transfection rates and achieve
adequate expression of the therapeutic molecule within a
cell [46]. Common vectors include plasmids and phos-
pholipid agents, which have short-lived eﬀects, and viruses
(retroviruses, adenoviruses, EBV), which have demonstrated
more lasting genetic expression. Clinical experience with
these therapies to date is limited with studies limited to
smallpatientcohortswhohavefailedconventionaltherapies.
However, results in treatment of hepatic neoplasms and their
metastases appear promising [47, 48].
3.4. Ablative Techniques. L o c a lt u m o u ra b l a t i o ni sa na l t e r -
native method of achieving tumour control in those patients
with early stage malignant disease, particularly in the liver,
who are not candidates for resection. IR mediated tumour
ablation induces tumour necrosis by the application of
energy and modalities employed include radiofrequency
(RF), laser, microwave, ultrasound and cryotherapy [49].
Radiofrequency ablation (RFA) involves administration of
electromagnetic energy in the radiofrequency range to a
tumour by means of a locally placed electrode connected
in a closed loop circuit to a monopolar or bipolar energy
source [50]. Tissues immediately surrounding the electrode
tip are heated to temperatures in excess of 60 degrees Celsius
with consequent thermal damage to the surrounding tissues
and cell death [50]. RFA has been demonstrated to be safe
with a mortality rate of 0.3% and a major complication rate
of 2.2% [51], and has gained acceptance as a method of
managing hepatic and lung malignant disease, with eﬃcacy
also described in the treatment of adrenal, renal, and skeletal
lesions [25, 52, 53]. While RFA is the most commonly
used ablative means, other modalities are ﬁnding increasing
clinical use. Cryoablation results in cell death through the
application of subfreezing temperatures, achieved by use
of argon gas under high pressure [54]. Alternating cycles
of freezing and thawing results in cell death due to the
associated mechanical stresses upon cell membranes with
phase change and ice formation and microvascular throm-
bosis induces tissue ischaemia which limits bleeding [55].
The application of electromagnetic energy in the microwave
range (at least 900MHz) agitates water molecules in targeted
tissues, resulting in frictional heat and cell death via coagula-
tion necrosis [56]. Though direct comparison of modalities
is diﬃcult, as a therapeutic tool, microwave ablation has
been shown comparable in eﬃcacy to RFA, particularly for
the treatment of hepatocellular carcinoma [57], however,
RFA achieves a lower local recurrence rate, higher survival
rate, and extensive necrosis after only a few treatment
sessions [58]. Potential added beneﬁts of microwave ablation
over RFA include larger tumour ablation volumes, optimal
heating of cystic masses, and less procedural pain [59]. The
involutional changes that occur following necrosis should be
monitored by serial imaging following ablation, with speciﬁc
postablation CT and MR imaging protocols being developed
at many institutions in an eﬀort to conﬁrm completeness of
ablation and to detect residual or recurrent disease [8, 60].
4. InterventionalRadiology inthe
Management of the Complications of Cancer
Malignancy can induce dysfunction of many organs and
bodily systems. Though debilitating, a signiﬁcant portion
of these complications are reversible, many by minimally
invasive IR methods. Such treatment can relieve symptoms,
alleviate pain, and improve operability of patients, thus
having a signiﬁcant positive impact on quality of life.
4.1. Biliary Obstruction. The majority of patients presenting
with malignant biliary obstruction have an underlying
pancreatic neoplasm extrinsically compressing the distal
bile duct and can be treated by endoscopic means [61].
Metastatic disease at the hepatic hilar nodes or in the
peripancreatic nodes may cause obstructive jaundice from
extrinsic pressure on the proximal portions of the biliary
tree and may require percutaneous intervention if less
invasive endoscopic means fails to achieve adequate biliary
decompression. Contrast injection into an intra-hepatic
bile duct at percutaneous transhepatic cholangiography will
delineate the anatomy of the biliary tree, determining the
location of obstruction, and helping to guide intervention
[62]. Percutaneous transhepatic biliary drainage (PBD) is an
eﬀectivemethodfortheprimaryorpalliativemanagementof
many biliary abnormalities demonstrated with cholangiog-
raphy. This procedure involves selective cannulation of the
biliary tree with catheter manipulation, then placement of
a catheter or stent to facilitate internal or external drainage
of biliary ﬂow and so allow decompression of the biliary
system [8] .M e t a ls t e n t sh a v eas i x - m o n t hp a t e n c yr a t eo f
50% and are thus almost exclusively used for malignant
disease [63, 64]. The percutaneous treatment of biliary
lesions is frequently staged, requiring several sessions to
achievetherapeuticgoals,though,inthemajorityofpatients,
liver function indices improve following a single treatment
[62]. PBD can be associated with major complications
including sepsis, haemorrhage and localised infective and
inﬂammatory processes (abscess, peritonitis, cholecystitis,
and pancreatitis) [64]. The incidence of complications is
higher in the oncology than in the general population,
perhaps related to advanced malignancy and the potential
presence of coexisting immunosuppression [64, 65]. The
incidence of cholangitis in oncology patients undergoing
PBD approaches 50%, such infection observed twice as
commonly in those with internal and external drainage
than in those with external drainage alone [66]. The longer
the duration of PBD is the more likely the patient is to
develop cholangitis [67]. The incidence of infected bile in
patients with malignant biliary obstruction is 25% to 36%6 Radiology Research and Practice
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Figure 4: 21-year-old woman with cervical cancer develops ureteric obstruction due to local disease invasion. (a) Contrast injection
immediately following percutaneous nephrostomy conﬁrms 8 french catheter in good position within renal collecting system. (b) Contrast-
enhanced CT scan conﬁrms percutaneous nephrostomy catheter in positioned within left renal collecting system. Patient is post total
abdominal hysterectomy and bilateral salpingo-oophorectomy.
[68]. Prior to initiating percutaneous biliary procedures, all
patients should be administered appropriate prophylactic
antibiotics to minimise septic complications, including cover
for escherichia coli, klebsiella, enterococcus, streptococcus,
enterobacter and pseudomonas aeruginosa [8].
4.2. Renal Obstruction. Malignant ureteral obstruction is an
ominous sign in the cancer patient and may be due to
extrinsic tumor compression, retroperitoneal adenopathy,
or direct tumor invasion [69]. Ureteral obstruction can be
induced by a wide range of malignancies, most commonly
those of gastrointestinal, urologic, or gynaecologic origin,
and may be unilateral or bilateral. Management requires
urinary decompression, often by means of percutaneous
nephrostomy (PCN). PCN is the most common renal
intervention performed by IR and, by providing direct access
to the urinary tract, allows drainage of tract contents as well
as providing access for further uroradiologic intervention
via the route established [70]. Indications for PCN in the
emergent setting include urinary tract sepsis, pyonephrosis,
deteriorating renal function, or electrolyte disturbances such
as hyperkalemia and metabolic acidosis [8]. Potential ben-
eﬁts of urinary decompression and diversion by this means
include reduction in the incidence of gram-negative septi-
caemia due to renal obstruction, partial recovery of renal
function, reversal of metabolic disturbance, and reduced
inpatient admission times. Image guidance may be provided
with ﬂuoroscopy, ultrasound, or often a combination of
both modalities [71]( Figure 4). The size and type of the
drainage catheter should be chosen appropriately according
to the nature of the ﬂuid to be drained [70]. In cases of
malignant ureteric obstruction, when retrograde stenting is
unsuccessful or not feasible, percutaneous dilatation of the
stricture may be achieved antegradely through the PCN tract
where, under ﬂuoroscopic guidance, a catheter is manipu-
lated across the stenotic region and the lesion is progressively
dilatedbycatheteradvancement,ureteraldilator,orbyinﬂat-
ing balloons of appropriate diameter and length [70]. After
dilatation, an internal ureteral stent, or internal-external
nephroureteral catheter is placed to prevent restenosis [70,
72]. Plastic stents are favoured over metal ones because they
induce less urothelial hyperplasia and can be easily replaced.
In a series of 102 cases of malignant ureteral obstruction
(68% bilateral), initial management with PCN or ureteral
stent achieved successful decompression of the system in
95% of cases [73]. The rate of successful completion of PCN
in oncology is mainly determined by the degree of dilatation
of the collecting system and by the patient’s body habitus
[74]. However, in the above series, signiﬁcant complications
suchasinfectionandcatheterblockagewereobservedin53%
of patients and overall survival was poor with a median of
seven months [73]; these outcomes may appear on initial
reﬂection to be disappointing, but are most likely explained
by advanced stage of malignancy in most patients.
4.3. Upper Gastrointestinal Obstruction. Patients with head,
neck, or oesophageal malignant lesions are, due to lumi-
nal obstruction or swallow impairment, frequently unable
to tolerate adequate oral intake and require nutritional
support, often by gastrostomy or gastrojejunostomy [75].
The interventional radiologist can play an important role
in the provision of enteral alimentation to these patients
(Figure 5). Percutaneous image-guided placement of feeding
tubes has demonstrated higher technical success rates and is
considered safer than endoscopic or surgical placement [76].
In addition, it may be successfully performed in patients in
whom conventional endoscopy is impossible [75]. Among
the more common early complications of gastrostomy inser-
tion are infection and mild discomfort on feeding, which
havebeenobservedin23%and33%ofcasesrespectively[77,
78]. Tube dislodgement is relatively common; however, if the
tract is established for more than two weeks, it is frequentlyRadiology Research and Practice 7
Figure 5: 73-year-old man with pancreatic cancer: percutaneous
gastrojejunostomy catheter placed for feeding. Contrast injection
following placement of percutaneous gastrojejunostomy tube con-
ﬁrms that the tip of the tube is in excellent position in the jejunum
(arrow). Note the gas-ﬁlled stomach (white arrow) and the locking
pigtail catheter in stomach which serves to maintain catheter in
position and prevent dislodgement.
possible to access the tract and reinsert the tube without
the need for repuncture of the stomach [8]. Complication
rates are similar with gastrostomy and gastrojejunostomy.
Malignant small bowel obstruction, as seen in patients
with peritoneal carcinomatosis, often of ovarian origin, is a
further indication for gastrostomy or gastrojejunostomy as a
means of decompression, with a technical success rate in the
region of 98% [79]. The presence of ascites in such patients
m a n d a t e sp a r a c e n t e s i sp r i o rt op r o c e d u r ea sp e r i t o n e a lﬂ u i d
leads to technical diﬃculty and the risk of pericatheter
leakage and the possibility of peritonitis [80–82]. Gastropexy
is advised prior to gastrostomy to reduce the likelihood
of catheter dislodgement from the anterior abdominal wall
and to reduce risk of peritonitis and peri-catheter leakage
[8, 80, 82].
4.4. Pleural Space Intervention. Malignant pleural eﬀusions,
often related to pleural and lymphatic involvement, are a
signiﬁcant source of morbidity in the oncology patient,
presenting with dyspnoea, cough, and chest pain [83]. As
a malignant pleural eﬀusion is a preterminal event with a
mean survival of three months, the usual aim of treatment
is palliation, and relief of symptoms and prevention of rec-
ollection [84, 85]. Successful drainage can be achieved by IR
with catheter placement under ﬂuoroscopic, ultrasound or
CTguidance.Image-guidedneedleaspirationofpleuralﬂuid
collections may also be performed to evaluate for the pres-
ence of malignant cells using cytology, thus aiding in the ini-
tialdiagnosisofmalignancyorstagingofknowndisease[85].
Therapeutic thoracocentesis provides temporary symp-
tomatic relief until the eﬀusion reaccumulates, as is often
the case in the setting of malignant eﬀusions, necessitating
a repeat procedure. Deﬁnitive treatment requires pleurodesis
[86]. Prevention of recurrent pleural eﬀusions can be
achievedbychemicalortalcpleurodesis.Priortopleurodesis,
large eﬀusions require drainage to optimise success rates
of pleurodesis and to prevent accumulation of therapeutic
agents within the pleural space. Based on eﬃcacy and the
likelihood of recurrence, thoracoscopic pleurodesis is the
preferred technique but has the drawback of requirement
for a general anaesthetic [86]. IR pleurodesis, entailing
instillation of the sclerosing agent via a thoracostomy tube
once complete evacuation of the eﬀusion has occurred, can
be performed at the bedside and is generally well tolerated
[8]. Available evidence supports the need for chemical
sclerosants to achieve successful pleurodesis, with talc as
the agent of choice [86]. Other agents employed include
tetracycline, bleomycin, and mustine.
4.5. Pain. A signiﬁcant source of cancer-related morbidity,
particularly in advanced disease, is pain. Prevalence can
range from 40% to as high as 90% with advanced disease
[87, 88], and when inadequately controlled, the impact of
pain can be profound. Opiates, with their considerable side
eﬀect proﬁle, remain the mainstay of treatment and pain can
be well managed in 80% to 90% of cancer patients according
to the principles of the World Health Organisation (WHO)
analgesic ladder [89–91]. Patients who have pain that is not
controlled by these means, or who have well-controlled pain
but with intolerable analgesic side eﬀects, may beneﬁt from
interventional pain management measures. As techniques
expand, IR is assuming an evolving role in the management
of cancer-associated pain. However, while IR has a role in
the treatment of oncological pain, it is noteworthy that
IR interventions may themselves be a source of signiﬁcant
painanddiscomfortamongpatients,particularlyprocedures
involving drainage of the renal and biliary tracts [92].
Optimal analgesia during and after such procedures is
essential. Percutaneous vertebroplasty, in recent years, has
emerged as an eﬀective minimally invasive treatment for
severe and refractory pain secondary to vertebral fracture
[93, 94]. In particular, its use has been met with considerable
success in the treatment of painful osteoporotic vertebral
compression fractures, where fracture stability is achieved by
introduction of cement. It has also found less frequent use
in the treatment of fractures secondary to neoplastic disease
[94, 95]. Osteolytic processes, such as myeloma, often induce
fractures, resulting in instability and pain. Vertebroplasty has
been shown to reduce requirements for analgesia and is now
being utilised in the treatment of vertebral fractures which
result from malignant osseous inﬁltration [95]. Again, the
complication risk is higher among oncology patients than in
thegeneralpopulation,withratesof5%and1%,respectively
for major complications [95]. The more signiﬁcant com-
plications include leakage of cement into the spinal canal,
pulmonary embolus, and pulmonary oedema. The beneﬁcial
eﬀectsofpainreductionandimprovedmobilityareobserved
in50%–60%ofoncologypatientsundergoingvertebroplasty,
with better results achieved by treating subacute rather than
chronic fractures [96].
Neuropathic pain associated with upper abdominal
visceral tumours is frequently poorly responsive to analgesic
therapy [97]. When resistant to analgesics, celiac ganglion
neurolysis and nerve block can achieve successful palliation8 Radiology Research and Practice
of pain in the majority of patients, particularly that related
to pancreatic, gastric, oesophageal, and biliary malignancies
[97]. Agents employed include local alcohol and phenol,
which induce permanent nerve root destruction, and triam-
cinlone, which causes reversible nocireceptor blockade [98].
A variety of imaging modalities can be used to guide celiac
axisblock;CTismostcommonlyusedwitheitherananterior
or posterior approach, dependent on operator experience
and anatomic considerations in the individual patient [99].
Reported minor complications include transient diarrhoea
in 73% and orthostatic hypotension in 12% [100].
4.6. Venous Thromboembolic Disease. Malignancy is an
established risk factor for venous thromboembolism. Fifteen
percent of cancer patients develop a symptomatic venous
thrombosis in the course of their therapy, and 50% have
evidence of venous thrombosis at autopsy [101]. Vena caval
ﬁlters, intravascular devices designed to prevent pulmonary
embolus by trapping venous emboli, are an accepted method
of managing venous thromboembolism in the oncology
patient. Indications for insertion include the occurrence
of a lower limb deep venous thrombosis in patients for
whom anticoagulation is contraindicated, in those in whom
a complication of anticoagulation has occurred, or in those
who develop recurrent PEs despite adequate anticoagulation
[102]. In experienced hands, the technical success rate of
inferior vena caval ﬁlter placement is over 97% [102].
Empirical use is not at present supported in the literature.
Recent developments in endovascular technologies have
provided radiologists with an assortment of minimally inva-
sive, catheter-based strategies to manage venous thrombus,
including both deep venous thromboses and pulmonary
emoboli. These percutaneous treatment methods for venous
thrombotic conditions include catheter-directed thrombol-
ysis, percutaneous mechanical thrombectomy devices, and
adjuvant venous angioplasty and stenting. Catheter-directed
thrombolysis therapy involves the use of infusion catheters
and wires to achieve local high-dose delivery of thrombolytic
agents to the thrombus with the aim of achieving more rapid
lysis. This allows a more predictable thrombolytic eﬀect with
a lower risk of haemorrhagic complications and with higher
patency rates than systemic thrombolysis, with the added
beneﬁtofabilitytovisualisetheentirevenoussystempriorto
and after administration of the pharmacologic agent [103].
Percutaneous mechanical thrombectomy may be used as a
primarytherapyforanacutethromboticevent,forthrombus
involving large vessels such as the vena cava, or, more
commonly, for patients in whom, despite conventional anti-
coagulation or catheter-directed therapy, there is persistent
thrombus. Such therapy also has a role in patients with
contraindications to continuous anti-coagulation or the use
of thrombolytic agents. It is however suggested that, in
the absence of contraindications to the use of thrombolytic
agents, mechanical thrombectomy devices should be used
in conjunction with pharmacological thrombolysis [103].
Mechanical, chemical, and hybrid pharmacomechanical
thrombectomy devices are available for clot extraction with
variable success rates [104], though further discussion of
these devices is outside the scope of this paper.
5. Conclusion
With the expanding application of minimally invasive tech-
niquestotheinvestigationandmanagementofmalignancies,
the interventional radiologist is assuming a more prominent
role in the multidisciplinary team that cares for the patient
with cancer. The use of IR techniques in oncology patients
should be evidence based to ensure optimal outcome and
minimise potential complications.
References
[1] D. S. Chow and M. W. Itagaki, “Interventional oncology
research in the united states: slowing growth, limited focus,
and a low level of funding,” Radiology, vol. 257, no. 2, pp.
410–417, 2010.
[2] A. H. Mahnken, P. Bruners, and R. W. G¨ unther, “Techniques
of interventional tumor therapy,” Deutsches Arzteblatt, vol.
105, no. 38, pp. 646–653, 2008.
[3] S. Gupta, M. J. Wallace, J. F. Cardella, S. Kundu, D. L.
Miller, and S. C. Rose, “Quality improvement guidelines
for percutaneous needle biopsy,” Journal of Vascular and
Interventional Radiology, vol. 21, no. 7, pp. 969–975, 2010.
[4] J.D.HainsworthandF.A.Greco,“Treatmentofpatientswith
cancer of an unknown primary site,” New England Journal of
Medicine, vol. 329, no. 4, pp. 257–263, 1993.
[5] G. R. Varadhachary, J. L. Abbruzzese, and R. Lenzi, “Diag-
nostic strategies for unknown primary cancer,” Cancer, vol.
100, no. 9, pp. 1776–1785, 2004.
[6] J. Kohler, B. Krause, S. Grunwald et al., “Ultrasound and
mammography guided wire marking of non-palpable breast
lesions: analysis of 741 cases,” Ultraschall in der Medizin, vol.
28, no. 3, pp. 283–290, 2007.
[7] L. Denbratt, J. Svanvik, and G. R˚ adberg, “A simple way
to indicate pulmonary nodules at thoracoscopic wedge
resections,” Acta Radiologica, vol. 37, no. 2, pp. 234–236,
1996.
[ 8 ]O .J .O ’ C o n n o r ,J .M .B u c k l e y ,a n dM .M .M a h e r ,“ I n t e r -
ventional radiology in oncology,” Cancer Treatment and
Research, vol. 143, pp. 493–511, 2008.
[9] R. S. Arellano, M. Maher, D. A. Gervais, P. F. Hahn, and P.
R. Mueller, “The diﬃcult biopsy: let’s make it easier,” Current
Problems in Diagnostic Radiology, vol. 32, no. 5, pp. 218–226,
2003.
[10] C. S. White, C. A. Meyer, and P. A. Templeton, “CT ﬂuo-
roscopy for thoracic interventional procedures,” Radiologic
Clinics of North America, vol. 38, no. 2, pp. 303–322, 2000.
[11] E. K. Paulson, D. H. Sheafor, D. S. Enterline, H. P. McAdams,
and T. T. Yoshizumi, “CT ﬂuoroscopy-guided interventional
procedures: techniques and radiation dose to radiologists,”
Radiology, vol. 220, no. 1, pp. 161–167, 2001.
[ 1 2 ]A .H a k i m e ,F .D e s c h a m p s ,E .G .M .d eC a r v a l h o ,C .
Teriitehau, A. Auperin, and T. de Baere, “Clinical evaluation
of spatial accuracy of a fusion imaging technique combining
previously acquired computed tomography and real-time
ultrasound for imaging of liver metastases,” CardioVascular
and Interventional Radiology. In press.
[13] T. S. Elliott, M. S. Faroqui, R. F. Armstrong, and G. C.
Hanson, “Guidelines for good practice in central venous
catheterization. Hospital Infection Society and the Research
U n i to ft h eR o y a lC o l l e g eo fP h y s i c i a n s , ”Journal of Hospital
Infection, vol. 28, no. 3, pp. 163–176, 1994.Radiology Research and Practice 9
[14] S. R. Dariushnia, M. J. Wallace, N. H. Siddiqi et al., “Quality
improvement guidelines for central venous access,” Journal of
Vascular and Interventional Radiology, vol. 21, no. 7, pp. 976–
981, 2010.
[15] D. Hind, N. Calvert, R. McWilliams et al., “Ultrasonic locat-
ing devices for central venous cannulation: meta-analysis,”
BritishMedicalJournal,vol.327,no.7411,pp.361–364,2003.
[16] “Guidance on the use of ultrasound locating devices for
placing central venous catheters,” National Institute for
Clinical Excellence Technology Appraisal Guidance, no. 49,
National Institute for Clinical Excellence, 2002.
[17] S. O. Trerotola, J. Kuhn-Fulton, M. S. Johnson, H. Shah,
W. T. Ambrosius, and P. H. Kneebone, “Tunneled infusion
catheters:increasedincidenceofsymptomaticvenousthrom-
bosis after subclavian versus internal jugular venous access,”
Radiology, vol. 217, no. 1, pp. 89–93, 2000.
[ 1 8 ]J .W .B l o m ,C .J .M .D o g g e n ,S .O s a n t o ,a n dF .R .R o s e n d a a l ,
“Malignancies, prothrombotic mutations, and the risk of
venous thrombosis,” J o u r n a lo ft h eA m e r i c a nM e d i c a lA s s o -
ciation, vol. 293, no. 6, pp. 715–722, 2005.
[19] J. A. Heit, M. D. Silverstein, D. N. Mohr, T. M. Petterson, W.
M. O’Fallon, and L. J. Melton, “Risk factors for deep vein
thrombosis and pulmonary embolism: a population-based
case-control study,” Archives of Internal Medicine, vol. 160,
no. 6, pp. 809–815, 2000.
[20] M. Verso and G. Agnelli, “Venous thromboembolism associ-
ated with long-term use of central venous catheters in cancer
patients,” Journal of Clinical Oncology, vol. 21, no. 19, pp.
3665–3675, 2003.
[21] E.A.Akl,G.Kamath,V.Yosuicoetal.,“Thromboprophylaxis
for patients with cancer and central venous catheters: a
systematic review and a meta-analysis,” Cancer, vol. 112, no.
11, pp. 2483–2492, 2008.
[ 2 2 ]J .F .T i m s i t ,J .C .F a r k a s ,J .M .B o y e re ta l . ,“ C e n t r a l
vein catheter-related thrombosis in intensive care patients:
incidence, risks factors, and relationship with catheter-
related sepsis,” Chest, vol. 114, no. 1, pp. 207–213, 1998.
[23] J. L. Baskin, C. H. Pui, U. Reiss et al., “Management
of occlusion and thrombosis associated with long-term
indwelling central venous catheters,” Lancet, vol. 374, no.
9684, pp. 159–169, 2009.
[24] M. L. Linenberger, “Catheter-related thrombosis: risks, diag-
nosis, and management,” Journal of the National Comprehen-
sive Cancer Network, vol. 4, no. 9, pp. 889–901, 2006.
[25] D. B. Brown, J. F. Cardella, D. Sacks et al., “Quality
improvement guidelines for transhepatic arterial chemoem-
bolization, embolization, and chemotherapeutic infusion for
hepatic malignancy,” Journal of Vascular and Interventional
Radiology, vol. 20, no. 7 supplement, pp. S219.e1–S226.e10,
2009.
[26] C. Toso, G. Mentha, N. M. Kneteman, and P. Majno, “The
place of downstaging for hepatocellular carcinoma,” Journal
of Hepatology, vol. 52, no. 6, pp. 930–936, 2010.
[27] D. Doyon, A. Mouzon, A. M. Jourde, C. Regensberg, and
C. Frileux, “Hepatic arterial embolization in patients with
malignant liver tumors,” Annales de Radiologie, vol. 17, no.
6, pp. 593–603, 1974.
[28] R. Cabrera and D. R. Nelson, “Review article: the manage-
mentofhepatocellularcarcinoma,”AlimentaryPharmacology
and Therapeutics, vol. 31, no. 4, pp. 461–476, 2010.
[29] N. B. Amesur, A. B. Zajko, and B. I. Carr, “Chemo-
embolization for unresectable hepatocellular carcinoma with
diﬀerent sizes of embolization particles,” Digestive Diseases
and Sciences, vol. 53, no. 5, pp. 1400–1404, 2008.
[30] R. Rodr´ ıguez Carvajal, A. Orgaz, J. I. Leal et al., “Renal
embolization and nephrectomy in a single surgical act in
high-risk renal tumor pathology,” Annals of Vascular Surgery,
vol. 25, no. 2, pp. 222–228, 2011.
[31] D. A. Gervais, S. Kalva, and A. Thabet, “Percutaneous image-
guided therapy of intra-abdominal malignancy: imaging
evaluation of treatment response,” Abdominal Imaging, vol.
34, no. 5, pp. 593–609, 2009.
[32] J. Hague and R. Tippett, “Endovascular techniques in
palliative care,” Clinical Oncology, vol. 22, no. 9, pp. 771–780,
2010.
[33] E. R. Sigurdson, J. A. Ridge, N. Kemeny, and J. M. Daly,
“Tumor and liver drug uptake following hepatic artery and
portal vein infusion,” Journal of Clinical Oncology, vol. 5, no.
11, pp. 1836–1840, 1987.
[ 3 4 ]M .A .B i t t l e sa n dF .A .H o ﬀer, “Interventional radiology and
thecareofthepediatriconcologypatient,”Surgical Oncology,
vol. 16, no. 3, pp. 229–233, 2007.
[35] M. A. W¨ orns and P. R. Galle, “Future perspectives in
hepatocellular carcinoma,” Digestive and Liver Disease, vol.
42, no. 3, pp. 302–309, 2010.
[36] H. Ahmadzadehfar, H. J. Biersack, and S. Ezziddin,
“Radioembolization of liver tumors with Yttrium-90 micro-
spheres,” Seminars in Nuclear Medicine,v o l .4 0 ,n o .2 ,p p .
105–121, 2010.
[37] R. Salem and K. G. Thurston, “Radioembolization with
yttrium-90 microspheres: a state-of-the-art brachytherapy
treatment for primary and secondary liver malignancies—
part3:comprehensiveliteraturereviewandfuturedirection,”
Journal of Vascular and Interventional Radiology, vol. 17, no.
10, pp. 1571–1593, 2006.
[38] J. F. W. Nijsen, A. D. van het Schip, W. E. Hennink, D.
W. Rook, P. P. van Rijk, and J. M. H. de Klerk, “Advances
in nuclear oncology: microspheres for internal radionuclide
therapy in liver tumours,” Current Medicinal Chemistry, vol.
9, no. 1, pp. 73–82, 2002.
[39] R. Cianni, C. Urigo, E. Notarianni et al., “Radioembolisation
using yttrium 90 (Y-90) in patients aﬀected by unresectable
hepatic metastases,” Radiologia Medica, vol. 115, no. 4, pp.
619–633, 2010.
[40] A. Deleporte, P. Flamen, and A. Hendlisz, “State of the art:
radiolabeled microspheres treatment for liver malignancies,”
Expert Opinion on Pharmacotherapy, vol. 11, no. 4, pp. 579–
586, 2010.
[ 4 1 ]W .B u l t ,M .A .D .V e n t e ,B .A .Z o n n e n b e r g ,A .D .v a nH e t
Schip,andJ.F.W.Nijsen,“Microsphereradioembolizationof
liver malignancies: current developments,” Quarterly Journal
of Nuclear Medicine and Molecular Imaging,v o l .5 3 ,n o .3 ,p p .
325–335, 2009.
[42] M. A. D. Vente, T. C. de Wit, M. A. A. J. van den
Bosch et al., “Holmium-166 poly(L-lactic acid) microsphere
radioembolisation of the liver: technical aspects studied in a
large animal model,” European Radiology, vol. 20, no. 4, pp.
862–869, 2010.
[43] M. Cosimelli, R. Golﬁeri, P. P. Cagol et al., “Multi-centre
phase II clinical trial of yttrium-90 resin microspheres alone
in unresectable, chemotherapy refractory colorectal liver
metastases,”BritishJournalofCancer,vol.103,no.3,pp.324–
331, 2010.
[44] D. W. Bell, “Our changing view of the genomic landscape
of cancer,” Journal of Pathology, vol. 220, no. 2, pp. 231–243,
2010.10 Radiology Research and Practice
[45] C. J. Brown, S. Lain, C. S. Verma, A. R. Fersht, and D. P. Lane,
“Awakening guardian angels: drugging the P53 pathway,”
Nature Reviews Cancer, vol. 9, no. 12, pp. 862–873, 2009.
[46] S. Bic ¸ero˘ glu and A. Memis ¸, “Gene therapy: applications
in interventional radiology,” Diagnostic and Interventional
Radiology, vol. 11, no. 2, pp. 113–118, 2005.
[47] G. Tian, J. Liu, J. S. Zhou, and W. Chen, “Multiple hepatic
arterial injections of recombinant adenovirus p53 and 5-
ﬂuorouracil after transcatheter arterial chemoembolization
for unresectable hepatocellular carcinoma: a pilot phase II
trial,” Anti-Cancer Drugs, vol. 20, no. 5, pp. 389–395, 2009.
[48] M. Yu, W. Chen, and J. Zhang, “P53 gene therapy for pul-
monary metastasis tumor from hepatocellular carcinoma,”
Anti-Cancer Drugs, vol. 21, no. 9, pp. 882–884, 2010.
[ 4 9 ]S .N .G o l d b e r g ,C .J .G r a s s i ,J .F .C a r d e l l ae ta l . ,“ I m a g e -
guided tumor ablation: standardization of terminology and
reporting criteria,” Journal of Vascular and Interventional
Radiology, vol. 20, no. 7 supplement, pp. S377–S390, 2009.
[50] A. R. Gillams, “Image guided tumour ablation,” Cancer
Imaging, vol. 5, pp. 103–109, 2005.
[51] T. Livraghi, L. Solbiati, M. F. Meloni, G. S. Gazelle, E.
F. Halpern, and S. N. Goldberg, “Treatment of focal liver
tumorswithpercutaneousradio-frequencyablation:compli-
cations encountered in a multicenter study,” Radiology, vol.
226, no. 2, pp. 441–451, 2003.
[ 5 2 ]V .E .d eM e i j e r ,C .V e r h o e f ,J .W .K u i p e r ,I .P .J .A l w a y n ,
G. Kazemier, and J. N. M. IJzermans, “Radiofrequency
ablation in patients with primary and secondary hepatic
malignancies,” Journal of Gastrointestinal Surgery, vol. 10, no.
7, pp. 960–973, 2006.
[ 5 3 ]S .C .R o s e ,P .A .T h i s t l e t h w a i t e ,P .E .S e w e l l ,a n dR .B .
Vance, “Lung cancer and radiofrequency ablation,” Journal
of Vascular and Interventional Radiology,v o l .1 7 ,n o .6 ,p p .
927–951, 2006.
[54] M. Beland, P. R. Mueller, and D. A. Gervais, “Thermal abla-
tion in interventional oncology,” Seminars in Roentgenology,
vol. 42, no. 3, pp. 175–190, 2007.
[55] S. M. Weber and F. T. Lee, “Expanded treatment of hepatic
tumors with radiofrequency ablation and cryoablation,”
Oncology, vol. 19, no. 11, pp. 27–32, 2005.
[56] C. J. Simon, D. E. Dupuy, and W. W. Mayo-Smith,
“Microwave ablation: principles and applications,” Radio-
graphics, vol. 25, pp. S69–S83, 2005.
[57] C. Boutros, P. Somasundar, S. Garrean, A. Saied, and
N. J. Espat, “Microwave coagulation therapy for hepatic
tumors: review of the literature and critical analysis,” Surgical
Oncology, vol. 19, no. 1, pp. e22–e32, 2010.
[ 5 8 ]K .O h m o t o ,N .Y o s h i o k a ,Y .T o m i y a m ae ta l . ,“ C o m p a r i -
son of therapeutic eﬀects between radiofrequency ablation
and percutaneous microwave coagulation therapy for small
hepatocellular carcinomas,” Journal of Gastroenterology and
Hepatology, vol. 24, no. 2, pp. 223–227, 2009.
[59] A. M. Venkatesan, J. Locklin, D. E. Dupuy, and B. J. Wood,
“Percutaneous ablation of adrenal tumors,” Techniques in
Vascular and Interventional Radiology, vol. 13, no. 2, pp. 89–
99, 2010.
[60] D. E. Dupuy and S. N. Goldberg, “Image-guided radiofre-
quency tumor ablation: challenges and opportunities—part
II,” Journal of Vascular and Interventional Radiology, vol. 12,
no. 10, pp. 1135–1148, 2001.
[61] A. C. Venbrux and F. A. Osterman, “Malignant obstruction
of the hepatobiliary system,” in Abram’s Angiography: Inter-
ventional Radiology, S. Baum and M. J. Pentecost, Eds., pp.
472–482, Little, Brown, Boston, Mass, USA, 1997.
[ 6 2 ]W .E .A .S a a d ,M .J .W a l l a c e ,J .C .W o j a k ,S .K u n d u ,a n d
J. F. Cardella, “Quality improvement guidelines for per-
cutaneous transhepatic cholangiography, biliary drainage,
and percutaneous cholecystostomy,” Journal of Vascular and
Interventional Radiology, vol. 21, no. 6, pp. 789–795, 2010.
[63] E. N. Liatsikos, D. Karnabatidis, K. Katsanos et al., “Ureteral
metal stents: 10-year experience with malignant ureteral
obstructiontreatment,”JournalofUrology,vol.182,no.6,pp.
2613–2618, 2009.
[64] P. Rossi, M. Bezzi, M. Rossi et al., “Metallic stents in malig-
nant biliary obstruction: results of a multicenter European
study of 240 patients,” Journal of Vascular and Interventional
Radiology, vol. 5, no. 2, pp. 279–285, 1994.
[65] C. D. Becker, A. Gl¨ attli, R. Maibach, and H. U. Baer, “Per-
cutaneous palliation of malignant obstructive jaundice with
the Wallstent endoprosthesis: follow-up and reintervention
in patients with hilar and non-hilar obstruction,” Journal of
Vascular and Interventional Radiology, vol. 4, no. 5, pp. 597–
604, 1993.
[66] C. H. Carrasco, J. Zornoza, and W. J. Bechtel, “Malignant
biliary obstruction: complications of percutaneous biliary
drainage,” Radiology, vol. 152, no. 2, pp. 343–346, 1984.
[67] T. Nomura, Y. Shirai, and K. Hatakeyama, “Bacteribilia and
cholangitis after percutaneous transhepatic biliary drainage
for malignant biliary obstruction,” Digestive Diseases and
Sciences, vol. 44, no. 3, pp. 542–546, 1999.
[ 6 8 ]D .A .N i c h o l s ,R .M a c C a r t y ,a n dT .A .G a ﬀey, “Cholangio-
graphic evaluation of bile duct carcinoma,” American Journal
of Roentgenology, vol. 141, no. 6, pp. 1291–1294, 1983.
[69] P. Russo, “Urologic emergencies in the cancer patient,”
Seminars in Oncology, vol. 27, no. 3, pp. 284–298, 2000.
[ 7 0 ]B .K .P a r k ,S .H .K i m ,a n dM .H .M o o n ,“ N o n v a s c u l a r
interventions of the urinary tract,” Journal of Korean Medical
Science, vol. 17, no. 6, pp. 727–736, 2002.
[71] C. Kalogeropoulou, P. Kallidonis, and E. N. Liatsikos,
“Imaging in percutaneous nephrolithotomy,” Journal of
Endourology, vol. 23, no. 10, pp. 1571–1577, 2009.
[72] S. H. Kim, J. H. Park, and M. C. Han, “Antegrade balloon
dilatation and ureteral stenting for the benign ureteral
strictures,” Journal of the Korean Radiological Society, vol. 30,
pp. 57–63, 1994.
[73] L. M. Wong, L. K. Cleeve, A. D. Milner, and A. G.
Pitman, “Malignant ureteral obstruction: outcomes after
intervention. Have things changed?” Journal of Urology, vol.
178, no. 1, pp. 178–183, 2007.
[74] E. K. Lang and E. T. Price, “Redeﬁnitions of indications for
percutaneous nephrostomy,” Radiology, vol. 147, no. 2, pp.
419–426, 1983.
[75] S. C. Chan, S. F. Ko, S. H. Ng et al., “Fluoroscopically guided
percutaneous gastrostomy with modiﬁed gastropexy and a
large-bore balloon-retained catheter in patients with head
and neck tumors,” Acta Radiologica, vol. 45, no. 2, pp. 130–
135, 2004.
[76] B. Wollman, H. B. D’Agostino, J. R. Walus-Wigle, D. W.
Easter, and A. Beale, “Radiologic, endoscopic, and surgical
gastrostomy: an institutional evaluation and meta-analysis of
the literature,” Radiology, vol. 197, no. 3, pp. 699–704, 1995.
[77] F. Gonc ¸alves, M. Mozes, I. Saraiva, and C. Ramos, “Gastros-
tomies in palliative care,” Supportive Care in Cancer, vol. 14,
no. 11, pp. 1147–1151, 2006.
[78] A. M. Silas, L. F. Pearce, L. S. Lestina et al., “Percutaneous
radiologic gastrostomy versus percutaneous endoscopic gas-
trostomy: a comparison of indications, complications andRadiology Research and Practice 11
outcomesin370patients,”EuropeanJournalofRadiology,vol.
56, no. 1, pp. 84–90, 2005.
[79] J. M. Ryan, P. F. Hahn, and P. R. Mueller, “Performing
radiologic gastrostomyor gastrojejunostomyin patients with
malignant ascites,” American Journal of Roentgenology, vol.
171, no. 4, pp. 1003–1006, 1998.
[80] M. F. Given, S. M. Lyon, and M. J. Lee, “The role of the
interventional radiologist in enteral alimentation,” European
Radiology, vol. 14, no. 1, pp. 38–47, 2004.
[81] C. S. Ho and E. Y. Yeung, “Percutaneous gastrostomy and
transgastric jejunostomy,” American Journal of Roentgenol-
ogy, vol. 158, no. 2, pp. 251–257, 1992.
[82] E. G. McFarland, M. J. Lee, G. W. Boland, and P. R. Mueller,
“Gastropexy breakdown and peritonitis after percutaneous
gastrojejunostomy in a patient with ascites,” American Jour-
nal of Roentgenology, vol. 164, no. 1, pp. 189–193, 1995.
[83] M. H. Uzbeck, F. A. Almeida, M. G. Sarkiss et al., “Manage-
ment of malignant pleural eﬀusions,” Advances in Therapy,
vol. 27, no. 6, pp. 334–347, 2010.
[84] K. G. Seaton, E. F. Patz, and P. C. Goodman, “Palliative
treatment of malignant pleural eﬀusions: value of small-
bore catheter thoracostomy and doxycycline sclerotherapy,”
American Journal of Roentgenology, vol. 164, no. 3, pp. 589–
591, 1995.
[85] G. Lombardi, F. Zustovich, M. O. Nicoletto, M. Donach,
G. Artioli, and D. Pastorelli, “Diagnosis and treatment of
malignant pleural eﬀusion: a systematic literature review and
new approaches,” American Journal of Clinical Oncology, vol.
33, no. 4, pp. 420–423, 2010.
[86] P. Shaw and R. Agarwal, “Pleurodesis for malignant pleural
eﬀusions,” Cochrane Database of Systematic Reviews,n o .1 ,
Article ID CD002916, 2004.
[87] I. J. Higginson, “Innovations in assessment: epidemiology
and assessment of pain in advanced cancer,” in Proceedings of
the 8th World Congress on Pain: Progress in Pain Research and
Management, T. S. Jensen, J. A. Turner, and Z. Wiesenfeld-
Hallin, Eds., IASP Press, Seattle, Wash, USA, 1997.
[88] A. Caraceni and R. K. Portenoy, “An international survey of
cancer pain characteristics and syndromes. IASP Task Force
on Cancer Pain. International Association for the Study of
Pain,” Pain, vol. 82, no. 3, pp. 263–274, 1999.
[89] M. Fallon, G. Hanks, and N. Cherny, “ABC of palliative care:
principles of control of cancer pain,” British Medical Journal,
vol. 332, no. 7548, pp. 1022–1024, 2006.
[90] C. S. Cleeland, R. Gonin, A. K. Hatﬁeld et al., “Pain and
its treatment in outpatients with metastatic cancer,” New
England Journal of Medicine, vol. 330, no. 9, pp. 592–596,
1994.
[91] R. H. Enting, W. H. Oldenmenger, C. C. D. van der Rijt et al.,
“A prospective study evaluating the response of patients with
unrelievedcancerpaintoparenteralopioids,”Cancer,vol.94,
no. 11, pp. 3049–3056, 2002.
[92] A. England, C. L. Tam, D. E. Thacker et al., “Patterns,
incidence and predictive factors for pain after interventional
radiology,” Clinical Radiology, vol. 60, no. 11, pp. 1188–1194,
2005.
[93] B. Kevane, D. Q. Ryder, and O. Gilligan, “Percutaneous
vertebroplasty in osteoporosis, myeloma and langerhans’ cell
histiocytosis,” Irish Medical Journal, vol. 102, no. 7, pp. 212–
215, 2009.
[ 9 4 ]S .M a s a l a ,F .M a s s a r i ,R .F i o r i ,M .M a m m u c a r i ,D .A .B a r -
tolucci,andG.Simonetti,“Futuredirectionsinpercutaneous
vertebroplasty,” Radiologia Medica, vol. 114, no. 6, pp. 976–
983, 2009.
[95] J. K. McGraw, J. A. Lippert, K. D. Minkus, P. M. Rami, T. M.
Davis, and R. F. Budzik, “Prospective evaluation of pain relief
in 100 patients undergoing percutaneous vertebroplasty:
results and follow-up,” Journal of Vascular and Interventional
Radiology, vol. 13, no. 9, part 1, pp. 883–886, 2002.
[96] D. Crandall, D. Slaughter, P. J. Hankins, C. Moore, and J. Jer-
man, “Acute versus chronic vertebral compression fractures
treated with kyphoplasty: early results,” Spine Journal, vol. 4,
no. 4, pp. 418–424, 2004.
[ 9 7 ]R .L .T i t t o n ,B .C .L u c e y ,D .A .G e r v a i s ,G .W .B o l a n d ,
and P. R. Mueller, “Interventional radiology case conferences
Massachusetts General Hospital celiac plexus block: a pal-
liative tool underused by radiologists,” American Journal of
Roentgenology, vol. 179, no. 3, pp. 633–636, 2002.
[98] J. G. Lieb II and C. E. Forsmark, “Review article: pain
and chronic pancreatitis,” Alimentary Pharmacology and
Therapeutics, vol. 29, no. 7, pp. 706–719, 2009.
[99] D. Akinci and O. Akhan, “Celiac ganglia block,” European
Journal of Radiology, vol. 55, no. 3, pp. 355–361, 2005.
[100] O. Akhan, M. N. Ozmen, N. Basgun et al., “Long-term
resultsofceliac gangliablock: correlationofgradeoftumoral
invasion and pain relief,” American Journal of Roentgenology,
vol. 182, no. 4, pp. 891–896, 2004.
[101] F. D. Moore Jr., R. T. Osteen, D. D. Karp, G. Steele Jr., and R.
E. Wilson, “Anticoagulants, venous thromboembolism, and
the cancer patient,” Archives of Surgery, vol. 116, no. 4, pp.
405–407, 1981.
[102] C. J. Grassi, T. L. Swan, J. F. Cardella et al., “Quality improve-
ment guidelines for percutaneous permanent inferior vena
gava ﬁlter placement for the prevention of pulmonary
embolism,” Journal of Vascular and Interventional Radiology,
vol. 14, no. 9, part 2, pp. S271–S275, 2003.
[103] S. A. Nazir, A. Ganeshan, S. Nazir, and R. Uberoi, “Endovas-
cular treatment options in the management of lower limb
deep venous thrombosis,” CardioVascular and Interventional
Radiology, vol. 32, no. 5, pp. 861–876, 2009.
[104] P. H. Lin, L. N. Ochoa, and P. Duﬀy, “Catheter-directed
thrombectomy and thrombolysis for symptomatic lower-
extremity deep vein thrombosis: review of current interven-
tional treatment strategies,” Perspectives in Vascular Surgery
and Endovascular Therapy, vol. 22, no. 3, pp. 152–163, 2010.